Evidence map›Paper›PMID 41723318›Full record

ArticleAnnals of surgical oncology2026

Commission on Cancer Quality Measure for Omission of Sentinel Lymph Node Biopsy (SNB) in Women Age 70 or Older with Hormone Receptor-Positive (HR+) Invasive Breast Cancer (IBC) Undergoing Breast-Conserving Surgery (BCS): Review of Historical Performance.

Gabrielle N Yee, Shelley Hwang, Lee G Wilke, Laura M Freedman, Anthony J Froix, Emily Ray, Kristine Kuchta, Laura Eldridge, Katharine A Yao

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gabrielle N YeeDepartment of Surgery, Endeavor Health, Evanston, IL, USA.
Shelley HwangDepartment of Surgery, Duke University, Durham, NC, USA.
Lee G WilkeDepartment of Surgery, University of Wisconsin-Madison, Madison, WI, USA.
Laura M FreedmanDepartment of Radiation Oncology, University of Miami, Coral Gables, FL, USA.
Anthony J FroixDepartment of Surgery, UT Southwestern, Dallas, TX, USA.
Emily RayDepartment of Medicine, University of North Carolina, Chapel Hill, NC, USA.
Kristine KuchtaBiostatistical Core, Endeavor Health, Evanston, IL, USA.
Laura EldridgeBiostatistical Core, Endeavor Health, Evanston, IL, USA.
Katharine A YaoDepartment of Surgery, Endeavor Health, Evanston, IL, USA. Katharine.yao@endeavorhealth.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn 2025, the Commission on Cancer (CoC) issued a quality measure recommending omission of sentinel node biopsy (SNB) in women 70 and over with cT1N0, hormone receptor positive (HR+), HER2neu negative invasive breast cancer undergoing breast conserving surgery. We examined historical performance of this measure.

methodsTrends in omission of SNB and estimated performance rates (EPR) by facility (the proportion of patients in whom SNB was omitted at a facility) were examined from 2012-2023. Multivariate analysis demonstrated facility factors most strongly associated with median compliance rate of 25%.

resultsA total of 185,859 patients from the National Cancer Data Base (NCDB) met the aforementioned inclusion criteria. From 2012-2023, SNB was omitted in 43,513 (23.4%) of eligible patients. SNB omission rates were 14% in 2012 versus 44% in 2023. An EPR of 30% was achieved by 655 (52.9%) CoC facilities, 40% by 516 (41.9%) facilities, 50% by 393 (31.7%) facilities, 60% by 278 (22.5%) facilities, 70% by 155 (12.5%) facilities, and 80% by only 85 (6.9%) facilities from 2021-2023. Facilities with > 50% private insurance (OR 1.7, 95% CI:1.23-2.34), academic/teaching designation (OR 2.12, 95% CI:1.36-3.3), high volume (> 250 annual cases) (OR 2.07, 95% CI:1.35-3.18) and in certain census areas of the country were significantly associated with higher likelihood of achieving 25% EPR, the median EPR amongst all site, on multivariate analysis (p < 0.05).

conclusionSNB was omitted on less than half of eligible HR+, HER2neu negative early-stage breast cancer patients over age 70 in 2023, indicating an opportunity for quality improvement.

Indexed as

Breast NeoplasmsMastectomy, SegmentalQuality Indicators, Health CareSentinel Lymph Node BiopsyAgedAged, 80 and overErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesHumansNeoplasm InvasivenessPrognosisReceptors, EstrogenReceptors, ProgesteroneERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneBreast neoplasmsBreast quality measuresNational cancer databaseSentinel node lymph node biopsySurgery

Identifiers

PMID41723318

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.